InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on shares of InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 target price for the company.

InspireMD Trading Down 6.8 %

Shares of NYSE NSPR opened at $3.00 on Friday. The company has a 50 day simple moving average of $2.83 and a two-hundred day simple moving average of $2.76. The stock has a market cap of $78.25 million, a price-to-earnings ratio of -4.00 and a beta of 1.00. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.80.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC purchased a new stake in InspireMD in the 4th quarter worth approximately $27,000. Legato Capital Management LLC acquired a new position in shares of InspireMD in the 4th quarter valued at $47,000. Schonfeld Strategic Advisors LLC boosted its holdings in InspireMD by 153.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after buying an additional 18,233 shares in the last quarter. Northern Trust Corp grew its position in InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after buying an additional 24,452 shares during the period. Finally, Essex Investment Management Co. LLC purchased a new position in InspireMD in the fourth quarter valued at $191,000. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.